Abstract: Methods, apparatus, systems, and articles of manufacture are disclosed to improve in-memory multiply and accumulate operations. An example apparatus includes a first multiplexer in a subarray of memory, the first multiplexer to receive first values representative of a column of a lookup table (LUT) including entries to represent products of four-bit numbers and return second values from an intersection of a row and the column of the LUT based on a first element of a first operand; shift and adder logic in the subarray, the shift and adder logic to shift the second values based on at least one of the first element of the first operand or a first element of a second operand; and accumulation storage in the subarray, the accumulation storage to store at least the shifted second values.

Abstract: A smart wearable device may include a smart ring device. The smart ring device may include a ring that includes a coupling mount. The smart ring device may also include an electronics unit selectively attachable to the coupling mount. The electronics unit may generate usage data representative of a movement and a physiological response of a user. In addition, the smart ring device may include a feedback system communicatively coupled to the electronics unit. The feedback system may display information related to the smart ring device.

Abstract: The present invention provides a method for preventing or treating Alzheimer’s disease and symptoms thereof comprising administering to a subject in need thereof a therapeutically effective amount of N?-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide or a its pharmaceutically acceptable salts, wherein the prevention and/or treatment of said disease and symptoms thereof is achieved by inhibition of amyloid-beta (A?) plaque aggregation, tau hyperphosphorylation, c-Abl kinase or a combination thereof. Also disclosed is the use of a therapeutically effective amount of N?-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide or its pharmaceutically acceptable salts to inhibit amyloid-beta (A?) plaque aggregation, tau hyperphosphorylation, c-Abl kinase or a combination thereof.

Abstract: A smart box system may include a smart box device. The smart box device may include a top portion, elongated side portions, and side portions. The top portion may include a top set of locking elements configured to mate with an external device to prevent the external device from moving relative the top portion of the smart box device. The elongated side portions may attach to the top portion. The side portions may selectively attach to distal ends of the elongated side portions.

Abstract: A weight system may include a concentric weight plate, a weight body, a locking mechanism, and a handle. The weight body may define a cavity. The locking mechanism may be disposed within the cavity. The locking mechanism may be configured to selectively attach the concentric weight plate to the weight body. The handle may be coupled to the weight body and configured to permit a user to move the weight system as a single unit.

Abstract: Example compute-in-memory (CIM) or processor-in-memory (PIM) techniques using repurposed or dedicated static random access memory (SRAM) rows of an SRAM sub-array to store look-up-table (LUT) entries for use in a multiply and accumulate (MAC) operation.

Abstract: Methods, apparatus, systems, and articles of manufacture are disclosed to improve in-memory multiply and accumulate operations. An example apparatus includes a first multiplexer in a subarray of memory, the first multiplexer to receive first values representative of a column of a lookup table (LUT) including entries to represent products of four-bit numbers and return second values from an intersection of a row and the column of the LUT based on a first element of a first operand; shift and adder logic in the subarray, the shift and adder logic to shift the second values based on at least one of the first element of the first operand or a first element of a second operand; and accumulation storage in the subarray, the accumulation storage to store at least the shifted second values.

Abstract: The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

Abstract: The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

Abstract: The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

Abstract: The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

Abstract: Peers (p) monitor responses received from other peers (s, q) to requests for information and rate the responding peers on their ability to provide information of interest. When a responding peer (s) is discovered to frequently provide good results, the requesting peer (p) attempts to move closer to the responding peer (s) by creating a direct connection (p-s) with that peer and thereby promote the “good” peer to an “immediate” peer. If such a promotion would result in too many direct connections, the least important immediate peer is demoted to an “indirect” peer. The criteria (Imp) used for evaluating the relative importance of at least the immediate peers is preferably a time weighted average (Imp*(t)=?·Imp(t)+?·Imp*(t?1)) that also measures consistency and reliability and preferably includes factors not only representative of the peer's ability to provide requested information (Hits), but also of its proximity to the source of that information (1/Hops) so that it can prove that information efficiently.

Abstract: Peers (p) monitor responses received from other peers (s, q) to requests for information and rate the responding peers on their ability to provide information of interest. When a responding peer (s) is discovered to frequently provide good results, the requesting peer (p) attempts to move closer to the responding peer (s) by creating a direct connection (p-s) with that peer and thereby promote the “good” peer to an “immediate” peer. If such a promotion would result in too many direct connections, the least important immediate peer is demoted to an “indirect” peer.